Jan Lehmann

Summary

Affiliation: Saarland University
Country: Germany

Publications

  1. ncbi request reprint [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany]
    J Lehmann
    Studiengruppe AB 12 96 der Arbeitsgemeinschaft Urologische Onkologie, Germany
    Urologe A 42:1074-86. 2003
  2. ncbi request reprint Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University, Kirrberger Strasse, 66421 Homburg Saar, Germany
    Crit Rev Oncol Hematol 47:171-9. 2003
  3. ncbi request reprint [Gemcitabine in advanced bladder cancer]
    J Lehmann
    Klinik für Urologie und Kinderurologie, Universitat des Saarlandes, Homburg Saar
    Urologe A 42:63-77. 2003
  4. ncbi request reprint Managing locally advanced bladder cancer
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University, Kirrberger Strasse, 66421 Homburg Saar, Germany
    Expert Rev Anticancer Ther 2:656-66. 2002
  5. pmc Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University 66421 Homburg Saar, Germany
    BMC Infect Dis 2:20. 2002
  6. ncbi request reprint The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma
    Jan Lehmann
    Department of Urology, Saarland University, Homburg Saar, Germany
    Cancer 101:1552-62. 2004
  7. ncbi request reprint Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University, Kirrberger Strasse, 66421 Homburg Saar, Germany
    World J Urol 20:144-50. 2002
  8. ncbi request reprint SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer
    Bastian Keck
    Department of Urology, University Hospital Erlangen, Erlangen, Germany
    Ann Surg Oncol 20:3669-74. 2013
  9. pmc Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells
    Henrik Suttmann
    Department of Urology and Pediatric Urology, Saarland University Hospital, Homburg Saar, Germany
    BMC Urol 8:5. 2008
  10. doi request reprint Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder
    Bastian Keck
    Department of Urology, University Hospital Erlangen, Erlangen, Germany
    Ann Surg Oncol 20:2440-5. 2013

Detail Information

Publications44

  1. ncbi request reprint [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany]
    J Lehmann
    Studiengruppe AB 12 96 der Arbeitsgemeinschaft Urologische Onkologie, Germany
    Urologe A 42:1074-86. 2003
    ..Sustained long-term survival was only found for patients with locally advanced cancer, lymphatic metastases, or solitary distant metastasis but not for visceral metastatic disease...
  2. ncbi request reprint Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University, Kirrberger Strasse, 66421 Homburg Saar, Germany
    Crit Rev Oncol Hematol 47:171-9. 2003
    ..Furthermore, data on medical resources utilization as accounted during systemic polychemotherapy and related toxic events will be reconsidered, particularly under the impression of decreasing health care resources worldwide...
  3. ncbi request reprint [Gemcitabine in advanced bladder cancer]
    J Lehmann
    Klinik für Urologie und Kinderurologie, Universitat des Saarlandes, Homburg Saar
    Urologe A 42:63-77. 2003
    ....
  4. ncbi request reprint Managing locally advanced bladder cancer
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University, Kirrberger Strasse, 66421 Homburg Saar, Germany
    Expert Rev Anticancer Ther 2:656-66. 2002
    ..Whether neoadjuvant or adjuvant systemic chemotherapy is the superior form of adjunctive therapy for locally advanced bladder cancer continues to be a matter of dispute...
  5. pmc Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University 66421 Homburg Saar, Germany
    BMC Infect Dis 2:20. 2002
    ..Inducible expression of human beta-defensin-2 (HBD-2) has been described in various epithelial organs but not for the urogenital tract...
  6. ncbi request reprint The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma
    Jan Lehmann
    Department of Urology, Saarland University, Homburg Saar, Germany
    Cancer 101:1552-62. 2004
    ..The predictive value of these parameters compared with proliferation markers, such as Ki-67, proliferating cell nuclear antigen (PCNA), topoisomerase II-alpha, and p100, has not been determined...
  7. ncbi request reprint Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University, Kirrberger Strasse, 66421 Homburg Saar, Germany
    World J Urol 20:144-50. 2002
    ..This article reviews adjuvant studies from the era of MVAC combination chemotherapy, as well as contemporary studies that discuss new antineoplastic agents for systemic adjuvant chemotherapy of locally advanced bladder cancer...
  8. ncbi request reprint SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer
    Bastian Keck
    Department of Urology, University Hospital Erlangen, Erlangen, Germany
    Ann Surg Oncol 20:3669-74. 2013
    ..The prognosis of muscle-invasive bladder cancer is poor. Molecular prognosticators have gained increasing attention for individualized therapeutic options because they can identify patients with different prognoses...
  9. pmc Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells
    Henrik Suttmann
    Department of Urology and Pediatric Urology, Saarland University Hospital, Homburg Saar, Germany
    BMC Urol 8:5. 2008
    ..This study evaluated the cytotoxic and antiproliferative efficacy of two well-characterized members of the Cecropin-family of antimicrobial peptides against bladder tumor cells and benign fibroblasts...
  10. doi request reprint Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder
    Bastian Keck
    Department of Urology, University Hospital Erlangen, Erlangen, Germany
    Ann Surg Oncol 20:2440-5. 2013
    ..We analyzed the effect of membranous E-cadherin loss and its nuclear accumulation in patients with locally advanced conventional urothelial carcinoma (UC) who were treated with radical cystectomy and adjuvant chemotherapy...
  11. pmc Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
    Bastian Keck
    Department of Urology, University Erlangen, Krankenhausstraße 12, Erlangen, 91054, Germany
    BMC Cancer 13:71. 2013
    ..Since the definition of different histologic subtypes of urothelial carcinomas by the World Health Organization (WHO) 2004 classification, description of molecular features and clinical behavior of these variants has gained more attention...
  12. ncbi request reprint Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05)
    Jan Lehmann
    Department of Urology, Städtisches Krankenhaus Kiel, Kiel, Germany
    Eur Urol 55:1293-9. 2009
    ..Recent publications suggest a benefit from surgical removal of urothelial carcinoma metastases (UCM) for a subgroup of patients...
  13. ncbi request reprint Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy
    Ulrike Zwergel
    Department of Urology and Pediatric Urology, University of Saarland, D 66421 Homburg Saar, Germany
    Eur Urol 52:1058-65. 2007
    ..To retrospectively assess the outcome of patients with initial PSA of 20 ng/ml or higher undergoing radical prostatectomy (RP) for prostate cancer (pCA)...
  14. ncbi request reprint Long-term survival under maintenance gemcitabine chemotherapy for metastatic transitional cell carcinoma
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University, Homburg Saar, Germany
    Int J Urol 13:1035-6. 2006
    ..Even elderly patients with impaired renal function may benefit in terms of tumor reduction and survival from systemic chemotherapy, which may be applied over a prolonged period of time...
  15. ncbi request reprint Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer
    Jan Lehmann
    Departments of Urology and Paediatric Urology, Saarland University, Homburg Saar, Germany
    BJU Int 97:42-7. 2006
    ....
  16. ncbi request reprint Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University, Kirrbergerstrasse, 66421 Homburg Saar, Germany
    Eur Urol 51:1281-8. 2007
    ..We retrospectively evaluated prognostic factors for progression-free and disease-specific survival in a large cohort of patients with transitional cell carcinoma (TCC) of the ureter...
  17. doi request reprint Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience
    Henrik Suttmann
    Department of Urology and Pediatric Urology, Saarland University Medical Center, Homburg Saar, Germany
    Cancer Biother Radiopharm 23:609-18. 2008
    ..The first clinical experience with the combination of both treatment modalities is reported...
  18. ncbi request reprint [Systemic chemotherapy for transitional cell carcinoma of the urothelium]
    J Lehmann
    Klinik für Urologie und Kinderurologie, Universitat des Saarlandes, Homburg, Deutschland
    Onkologie 26:18-25. 2003
    ....
  19. ncbi request reprint Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94
    Peter Albers
    Department of Urology, Klinikum Kassel GmbH, Kassel, Germany
    J Clin Oncol 26:2966-72. 2008
    ..Aim of this trial was to prove the advantage of one cycle of bleomycin, etoposide, and cisplatin (BEP) chemotherapy compared with RPLND in terms of recurrence...
  20. ncbi request reprint Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy
    Henrik Suttmann
    Department of Urology and Paediatric Urology, Saarland University Hospital, Homburg Saar, Germany
    BJU Int 100:1225-8. 2007
    ....
  21. ncbi request reprint Lymph node positive prostate cancer: long-term survival data after radical prostatectomy
    Ulrike Zwergel
    Department of Urology, University of Saarland, Homburg Saar, Germany
    J Urol 171:1128-31. 2004
    ..We retrospectively reviewed the outcome in our patients with prostate cancer and regional positive lymph nodes who underwent prostatectomy...
  22. doi request reprint Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow
    Margitta Retz
    Department of Urology, Technische Universitat Munchen, Rechts der Isar Medical Centre, Munich, Germany
    Eur Urol 60:231-8. 2011
    ....
  23. ncbi request reprint Telomerase activity and telomerase subunit gene expression levels are not related in prostate cancer: a real-time quantification and in situ hybridization study
    Joern Kamradt
    Clinic of Urology and Pediatric Urology, University of the Saarland, Homburg Saar, Germany
    Lab Invest 83:623-33. 2003
    ..Because in situ hybridization revealed strong hTERT expression in all cells of the tumor glands but also in high-grade prostatic intraepithelial neoplasia foci, this up-regulation seems to occur early in prostate carcinogenesis...
  24. doi request reprint Fast-track rehabilitation after robot-assisted laparoscopic cystectomy accelerates postoperative recovery
    Matthias Saar
    Department of Urology and Paediatric Urology, University of Saarland, Homburg Saar, Neunkirchen, Germany
    BJU Int 112:E99-106. 2013
    ..There was no evidence of a higher incidence of complications with the fast-track regimen and postoperative recovery was faster...
  25. ncbi request reprint Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines
    Jan Lehmann
    Department of Urology and Pediatric Urology, Saarland University, Homburg Saar, Germany
    Eur Urol 50:141-7. 2006
    ..In this study, we evaluated the cytotoxic and antiproliferative potency of magainin II in bladder tumor cells and normal fibroblasts...
  26. ncbi request reprint Improving the prognosis of patients after radical cystectomy. Part I: the role of lymph node dissection
    Henrik Suttmann
    Department of Urology and Paediatric Urology, Saarland University Hospital, Homburg Saar, Germany
    BJU Int 100:1221-4. 2007
    ..e. extension of lymph node dissection during radical surgery and perioperative chemotherapy. Both strategies are analysed and discussed in two mini-reviews, based on data from current publications and from theoretical considerations...
  27. ncbi request reprint The role of adjuvant chemotherapy for locally advanced bladder cancer
    J Lehmann
    Department of Urology, University Saarland, 66421 Homburg Saar, Germany
    World J Urol 19:133-40. 2001
    ..This review will summarize past, current, and future aspects of systemic adjuvant chemotherapy for transitional cell carcinoma of the bladder...
  28. ncbi request reprint Current TNM classification of renal cell carcinoma evaluated: revising stage T3a
    S Siemer
    Department of Urology, University of the Saarland, Kirrbergerstrasse, 66421 Homburg Saar, Germany
    J Urol 173:33-7. 2005
    ..We assessed the prognostic validity of a stage pT3a diagnosis based on perirenal fat infiltration...
  29. ncbi request reprint Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy
    S Siemer
    Department of Urology, University of the Saarland, Homburg Saar, Germany
    J Urol 171:2155-9; discussion 2159. 2004
    ..In a retrospective study we screened for subgroups of patients with renal cell carcinoma from a large single center patient population who may have benefited from ipsilateral adrenalectomy...
  30. ncbi request reprint Comprehensive genotypic analysis of human prostate cancer cell lines and sublines derived from metastases after orthotopic implantation in nude mice
    Ramona Lensch
    Department of Urology and Pediatric Urology, University of the Saarland, D 66421 Homburg Saar, Germany
    Int J Oncol 21:695-706. 2002
    ..Thus, the nude mice model is very useful to follow clonal evolution of genetic changes during increase of prostate cancer aggressiveness and possibly to clone genes associated with the progression of prostate cancer...
  31. doi request reprint The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma
    Bastian Keck
    Department of Urology, University Erlangen, Erlangen, Germany
    Int J Cancer 129:346-54. 2011
    ..TP53 mutation analysis showed mutations in 29%. In summary, PUC is an aggressive variant of bladder cancer with molecular features of advanced bladder cancer and evidence of WNT pathway activation in some of the cases...
  32. ncbi request reprint Prenatal diagnosis of congenital mesoblastic nephroma associated with renal hypertension in a premature child
    Stefan Siemer
    Department of Urology and Pediatric Urology, Saarland University, Homburg Saar, Germany
    Int J Urol 11:50-2. 2004
    ..Tumor nephrectomy was performed on day 11 after delivery when an increase in hypertension was observed in the newborn...
  33. ncbi request reprint [Therapy for systemic urothelial cancer recurrence]
    J Lehmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Homburg Saar
    Urologe A 44:369-74. 2005
    ....
  34. ncbi request reprint Outcome of renal tumors in young adults
    S Siemer
    Department of Urology, Saarland University, Germany
    J Urol 175:1240-3; discussion 1243-4. 2006
    ..Sporadic RCC is rare in young adults. We retrospectively reviewed the outcomes of patients 20 to 40 years old at our institution...
  35. ncbi request reprint Long term follow-up of combined radiochemotherapy for locally advanced bladder carcinoma
    M Retz
    Department of Urology, University of Kiel, Germany
    Cancer 89:1089-94. 2000
    ..The 5- and 10-year survival rates and the toxicity of combined radiochemotherapy for 53 consecutive patients with locally advanced bladder carcinoma were studied in a noncomparative trial...
  36. ncbi request reprint [Clinical trials for bladder cancer in Germany]
    J Lehmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Homburg Saar
    Urologe A 44:1435-8. 2005
    ..Future goals address extending the number of active centers in Germany as well as seeking international collaborations in order to enable timely recruitment of trials that demand an extensive sample size...
  37. doi request reprint [Extending the limits of lymphadenectomy during radical cystectomy: pitfalls in the interpretation of contemporary study results]
    H Suttmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Homburg Saar, Deutschland
    Urologe A 48:151-5. 2009
    ..This article provides a critical analysis of the contemporary data on the subject and outlines typical statistical pitfalls that must be considered when interpreting such research results...
  38. ncbi request reprint Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma
    M Retz
    Department of Urology, University Hospital Kiel, Germany
    Cancer Res 58:5662-6. 1998
    ..These results suggest a differential MUC7 gene expression with the onset of malignant transformation of the bladder urothelium...
  39. ncbi request reprint Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer
    James O Jin
    Section of Hematology Oncology, University of Chicago, IL 60637, USA
    Clin Genitourin Cancer 5:150-4. 2006
    ..Despite the general acceptance of gemcitabine/cisplatin in metastatic bladder cancer, its role and tolerability in the adjuvant setting, in which renal insufficiency is common, is unclear...
  40. ncbi request reprint Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95)
    Jan Lehmann
    Division of Biostatistics, Central Institute of Mental Health Manheim University of Heidelberg, Germany
    J Clin Oncol 23:4963-74. 2005
    ..We compared two adjuvant combination chemotherapies in patients with stage pT3a-4a and/or pathologic node-positive transitional-cell carcinoma of the bladder after radical cystectomy...
  41. doi request reprint Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer
    Sigrun Langbein
    Department of Urology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Int J Cancer 122:2422-8. 2008
    ..The coexistence of cancer cells with differentially regulated energy supplies provides new insights in carcinogenesis and novel anticancer targets...
  42. ncbi request reprint Relationship of NKX3.1 and MYC gene copy number ratio and DNA hypomethylation to prostate carcinoma stage
    Roland Kindich
    Clinic of Urology and Pediatric Urology, University of the Saarland, Homburg, Germany
    Eur Urol 49:169-75; discussion 175. 2006
    ..High stage prostate cancers have been reported to frequently harbor chromosome 8 alterations and hypomethylation of LINE-1 retrotransposons. The potential of these parameters for molecular staging of prostate carcinoma was investigated...
  43. ncbi request reprint Detection of occult tumor cells in lymph nodes from bladder cancer patients by MUC7 nested RT-PCR
    Margitta Retz
    Department of Anatomy, University of California San Francisco, Box 0452, San Francisco, CA 94143, USA
    Eur Urol 45:314-9. 2004
    ..We used the polymerase chain reaction (RT-PCR), a highly sensitive assay, to monitor MUC7 RNA...
  44. ncbi request reprint CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells
    Margitta M Retz
    Biomolecular Sciences Program, Cardiovascular Research Institute and Department of Anatomy, University of California San Francisco UCSF, San Francisco, CA 94143, USA
    Int J Cancer 114:182-9. 2005
    ..These properties identify CXCR4 as a potential target for the attenuation of bladder cancer metastases...